181 related articles for article (PubMed ID: 21169260)
1. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Yao S; Barlow WE; Albain KS; Choi JY; Zhao H; Livingston RB; Davis W; Rae JM; Yeh IT; Hutchins LF; Ravdin PM; Martino S; Lyss AP; Osborne CK; Abeloff M; Hortobagyi GN; Hayes DF; Ambrosone CB
Clin Cancer Res; 2010 Dec; 16(24):6169-76. PubMed ID: 21169260
[TBL] [Abstract][Full Text] [Related]
2. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
3. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
Su HI; Sammel MD; Velders L; Horn M; Stankiewicz C; Matro J; Gracia CR; Green J; DeMichele A
Fertil Steril; 2010 Jul; 94(2):645-54. PubMed ID: 19376514
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.
Choi JY; Barlow WE; Albain KS; Hong CC; Blanco JG; Livingston RB; Davis W; Rae JM; Yeh IT; Hutchins LF; Ravdin PM; Martino S; Lyss AP; Osborne CK; Abeloff MD; Hayes DF; Ambrosone CB
Clin Cancer Res; 2009 Aug; 15(16):5258-66. PubMed ID: 19671875
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
[TBL] [Abstract][Full Text] [Related]
6. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
[TBL] [Abstract][Full Text] [Related]
7. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
Ludovini V; Antognelli C; Rulli A; Foglietta J; Pistola L; Eliana R; Floriani I; Nocentini G; Tofanetti FR; Piattoni S; Minenza E; Talesa VN; Sidoni A; Tonato M; Crinò L; Gori S
BMC Cancer; 2017 Jul; 17(1):502. PubMed ID: 28747156
[TBL] [Abstract][Full Text] [Related]
8. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.
Tran A; Bournerias F; Le Beller C; Mir O; Rey E; Pons G; Delahousse M; Tréluyer JM
Br J Clin Pharmacol; 2008 Feb; 65(2):279-80. PubMed ID: 17875191
[No Abstract] [Full Text] [Related]
9. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
Haroun F; Al-Shaar L; Habib RH; El-Saghir N; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; Cascorbi I; Zgheib NK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):207-14. PubMed ID: 25428516
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Gor PP; Su HI; Gray RJ; Gimotty PA; Horn M; Aplenc R; Vaughan WP; Tallman MS; Rebbeck TR; DeMichele A
Breast Cancer Res; 2010; 12(3):R26. PubMed ID: 20459744
[TBL] [Abstract][Full Text] [Related]
12. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
Ambrosone CB; Barlow WE; Reynolds W; Livingston RB; Yeh IT; Choi JY; Davis W; Rae JM; Tang L; Hutchins LR; Ravdin PM; Martino S; Osborne CK; Lyss AP; Hayes DF; Albain KS
J Clin Oncol; 2009 Oct; 27(30):4973-9. PubMed ID: 19752340
[TBL] [Abstract][Full Text] [Related]
13. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.
Larsen V; Barlow WE; Yang JJ; Zhu Q; Liu S; Kwan ML; Ergas IJ; Roh JM; Hutchins LF; Kadlubar SA; Albain KS; Rae JM; Yeh IT; Ravdin PM; Martino S; Lyss AP; Osborne CK; Hortobagyi GN; Kushi LH; Hayes DF; Ambrosone CB; Yao S
Clin Breast Cancer; 2019 Aug; 19(4):225-235.e2. PubMed ID: 30928413
[TBL] [Abstract][Full Text] [Related]
14. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Yao S; Barlow WE; Albain KS; Choi JY; Zhao H; Livingston RB; Davis W; Rae JM; Yeh IT; Hutchins LF; Ravdin PM; Martino S; Lyss AP; Osborne CK; Abeloff MD; Hortobagyi GN; Hayes DF; Ambrosone CB
Breast Cancer Res Treat; 2010 Nov; 124(2):433-9. PubMed ID: 20309628
[TBL] [Abstract][Full Text] [Related]
15. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
16. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Zhou X; Wang X; Song Q; Yang H; Zhu X; Yu J; Song G; Di L; Ren J; Shao H; Lyerly HK
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):914-22. PubMed ID: 26396136
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
18. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
Afsar NA; Ufer M; Haenisch S; Remmler C; Mateen A; Usman A; Ahmed KZ; Ahmad HR; Cascorbi I
Eur J Clin Pharmacol; 2012 Apr; 68(4):389-95. PubMed ID: 22012257
[TBL] [Abstract][Full Text] [Related]
19. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Walko CM; Combest AJ; Spasojevic I; Yu AY; Bhushan S; Hull JH; Hoskins J; Armstrong D; Carey L; Collicio F; Dees EC
Cancer Chemother Pharmacol; 2012 May; 69(5):1189-96. PubMed ID: 22245954
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]